Sugi Predict

Sugi Predict / Compounds / SCHEMBL21766765

SCHEMBL21766765

SCHEMBL21766765

CC(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](Cc1c[nH]cn1)C(=O)N[C@H](CO)C(=O)N[C@H](C)C(=O)N[C@H](C)C(=O)N[C@H](C)C(=O)N[C@H](CSC1CC(=O)N(CCNC(=O)c2ccc(C(=O)O)c(-c3c4ccc(=O)cc-4oc4cc(O)ccc34)c2)C1=O)C(=O)N[C@H](C)C(=O)N[C@H](C)C(=O)N[C@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCC(=O)O)C(N)=O

nearest known ligand 0.49

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ WDR5 P61964 1/20 0.49
▸ HTRA2 O43464 8/20 0.43
▸ HTRA1 Q92743 8/20 0.43
▸ TERF2IP Q9NYB0 2/20 0.39
▸ MDM2 Q00987 1/20 0.38
▸ FOLH1 Q04609 2/20 0.38
▸ OPRL1 P41146 5/20 0.38
▸ ALB P02768 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21766700 0.96 WDR5 (0.50) WDR5HTRA2HTRA1TERF2IPMDM2
SCHEMBL21766801 0.96 WDR5 (0.50) WDR5HTRA2HTRA1TERF2IPMDM2
SCHEMBL21766502 0.96 WDR5 (0.50) WDR5HTRA2HTRA1TERF2IPMDM2
SCHEMBL21766807 0.96 WDR5 (0.50) WDR5HTRA2HTRA1TERF2IPMDM2
SCHEMBL26368243 0.95 WDR5 (0.50) WDR5HTRA2HTRA1TERF2IPMDM2
SCHEMBL26367843 0.95 WDR5 (0.50) WDR5HTRA2HTRA1TERF2IPMDM2
SCHEMBL21766751 0.94 WDR5 (0.50) WDR5HTRA2HTRA1TERF2IPMDM2
SCHEMBL21766497 0.94 WDR5 (0.51) WDR5HTRA2HTRA1TERF2IPMDM2
SCHEMBL21766804 0.94 WDR5 (0.48) WDR5HTRA2HTRA1TERF2IPMDM2
SCHEMBL21766692 0.92 WDR5 (0.50) WDR5HTRA2HTRA1TERF2IPMDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11771774-B2 Nerve labeling compositions and uses thereof AVELAS ACQUISITION CORPORATION (US) 2023-10-03 — — US disclosed
US-10994017-B2 Nerve labeling compositions and uses thereof AVELAS BIOSCIENCES, INC. (US) 2021-05-04 — — US disclosed
US-20200061200-A1 NERVE LABELING COMPOSITIONS AND USES THEREOF AVELAS ACQUISITION CORPORATION 2020-02-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200061200-A1 NERVE LABELING COMPOSITIONS AND USES THEREOF GAP43, NGF, PMP22 WDR5 1570/4885HTRA2 2525/4885HTRA1 4086/4885
US-10994017-B2 Nerve labeling compositions and uses thereof GAP43, NGF, PMP22 WDR5 1570/4885HTRA2 2525/4885HTRA1 4086/4885
US-11771774-B2 Nerve labeling compositions and uses thereof GAP43, NGF, PMP22 WDR5 1570/4885HTRA2 2525/4885HTRA1 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.